[{"indications": "Indications\u00a0severe extensive psoriasis resistant to other forms of therapy; palmoplantar\r\npustular psoriasis; severe congenital ichthyosis; severe Darier\u2019s\r\ndisease (keratosis follicularis)", "name": "ACITRETIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.2 Preparations for psoriasis", "Oral retinoids for psoriasis"], "cautions": "Cautions\u00a0exclude pregnancy before starting (test\r\nfor pregnancy within 2 weeks before treatment and monthly thereafter;\r\nstart treatment on day 2 or 3 of menstrual cycle)\u2014women (including those with history of infertility) should avoid\r\npregnancy and use effective contraception (ideally 2 methods of contraception,\r\none of which is a combined hormonal contraceptive or an intra-uterine\r\ndevice) for at least 1 month before, during, and for at least 3 years\r\nafter treatment (oral progestogen-only contraceptives not considered\r\neffective); avoid concomitant use of keratolytics; do not donate blood during and for 2 years after\r\nstopping therapy (teratogenic risk); check liver function at start, then every 2\u20134 weeks for first 2 months\r\nand then every 3 months; monitor serum-triglyceride\r\nand serum-cholesterol concentrations before treatment, 1 month after\r\nstarting, then every 3 months; diabetes\r\n(can alter glucose tolerance\u2014initial frequent blood glucose checks); investigate\r\natypical musculoskeletal symptoms; in children\r\nuse only in exceptional circumstances and monitor growth parameters\r\nand bone development (premature epiphyseal closure reported); avoid excessive exposure to sunlight and unsupervised use of sunlamps; interactions: Appendix 1 (retinoids)", "side-effects": "Side-effects\u00a0abdominal pain, diarrhoea, nausea, vomiting, dryness\r\nand inflammation of mucous membranes, peripheral oedema, reversible\r\nincrease in serum-cholesterol and serum-triglyceride concentrations\r\n(with high doses), headache, arthralgia, myalgia, dryness of conjunctiva\r\n(causing conjunctivitis and decreased tolerance to contact lenses),\r\nalopecia (reversible on withdrawal), abnormal hair texture, skin exfoliation,\r\npruritus, epidermal fragility, sticky skin, dermatitis, erythema,\r\nbrittle nails, paronychia; less commonly hepatitis,\r\ndizziness, visual disturbances, photosensitivity; rarely peripheral neuropathy; very rarely benign intracranial\r\nhypertension (discontinue if severe headache, nausea, vomiting, or\r\nvisual disturbances occur), bone pain, exostosis (skeletal hyperostosis\r\nand extra-osseous calcification reported following long-term treatment\r\nwith etretinate, and premature epiphyseal closure in children, see\r\nCautions above), night blindness, ulcerative keratitis; also\r\nreported taste disturbance, rectal haemorrhage, flushing,\r\nmalaise, drowsiness, granulomatous lesions, impaired hearing, tinnitus,\r\ninitial worsening of psoriasis, dry skin, sweating", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5995.htm", "doses": ["adult over 18 years (under\r\nexpert supervision), initially 25\u201330\u00a0mg daily (Darier\u2019s disease 10\u00a0mg\r\ndaily) for 2\u20134 weeks, then adjusted according to response, usual range\r\n25\u201350\u00a0mg daily; up to 75\u00a0mg daily for short periods in psoriasis and\r\nichthyosis (see notes above); child under 18 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0avoid\u2014teratogenic; effective contraception must be\r\nused\u2014see Cautions above"}]